Specific tyrosine kinases inhibitors (TKI) have been developed for the treatment of leukemias, initially CML, but Stat5 activation has been found to be associated with acquired drug resistance [39]. Here, STAT5B is linked to chronic myelogenous leukemia, BCR-ABL1 positive.